We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
VUMERITY (Biogen Australia Pty Ltd)
Product name
VUMERITY
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
197 (255 working days)
Active ingredients
diroximel fumarate
Registration type
NCE/NBE
Indication
VUMERITY (enteric capsule) is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.